


## SC-435

<b>Cat. No.:</b>	HY-129982
<b>CAS No.:</b>	289037-67-8
<b>Molecular Formula:</b>	C <sub>37</sub> H <sub>59</sub> N <sub>3</sub> O <sub>7</sub> S <sub>2</sub>
<b>Molecular Weight:</b>	722.01
<b>Target:</b>	Apical Sodium-Dependent Bile Acid Transporter
<b>Pathway:</b>	Membrane Transporter/Ion Channel
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 50 mg/mL (69.25 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.3850 mL	6.9251 mL	13.8502 mL
	5 mM	0.2770 mL	1.3850 mL	2.7700 mL
	10 mM	0.1385 mL	0.6925 mL	1.3850 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

SC-435 is an apical sodium-dependent Bile acid (BA) transporter inhibitor. SC-435 can alter hepatic cholesterol metabolism and lower plasma low-density lipoprotein-cholesterol concentrations<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

Bile acid transporter<sup>[1]</sup>

### REFERENCES

[1]. West KL, et, al. 1-[4-[4[(4R,5R)-3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]butyl]-4-aza-1-azoniabicyclo[2.2.2]octane methanesulfonate (SC-435), an ileal apical sodium-codependent bile acid transporter inhibitor alters hepatic cholesterol metabolism and lowers plasma low-density lipoprotein-cholesterol concentrations in guinea pigs. *J Pharmacol Exp Ther.* 2002 Oct;303(1):293-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA